Pharmaceutical formulation

Inventors

SHAH, Mahendra G.

Assignees

Semnur Pharmaceuticals Inc

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-11364251-B2

Patent

Publication Date

2022-06-21

Expiration Date


Abstract

Disclosed are aqueous pharmaceutical compositions which provide sustained released delivery of corticosteroid compounds. The pharmaceutical composition comprises an insoluble corticosteroid; a soluble corticosteroid; and at least one viscosity enhancing agent. Also provided are methods for using the pharmaceutical compositions in an epidural injection, intra-articular injection, intra-lesional injection, or an intra-ocular injection.

Core Innovation

The invention provides aqueous sustained-release corticosteroid formulations for delivery in a syringe. The formulations comprise an insoluble corticosteroid and a soluble corticosteroid together with at least one viscosity enhancing agent, and the viscosity enhancing agent is sodium hyaluronate or hyaluronic acid.

The aqueous compositions combine an insoluble corticosteroid and a soluble corticosteroid, with the insoluble corticosteroid present as an acetate ester form and the soluble corticosteroid present as a corresponding sodium phosphate form. The insoluble corticosteroid is provided as micrometer-sized particles, and the composition includes design constraints such as insoluble particle size and an insoluble-to-soluble corticosteroid ratio.

The document further describes that viscosity enhancing agent molecular weight and concentration are constrained, including ranges for sodium hyaluronate/hyaluronic acid molecular weight and concentration. It reports effects on injectability and stability characteristics, including mitigation of stringing, reduced injection force requirements, and a clean break.

Claims Coverage

The partial content provides two independent claims, each requiring an aqueous pharmaceutical composition in a syringe that contains multiple corticosteroids and a viscosity enhancing agent, with constrained viscosity-enhancer molecular weight and concentration.

Syringe with insoluble and soluble corticosteroids plus sodium hyaluronate or hyaluronic acid viscosity enhancer

A syringe comprising an aqueous pharmaceutical composition comprising an insoluble corticosteroid, a soluble corticosteroid, and at least one viscosity enhancing agent, wherein the at least one viscosity enhancing agent is sodium hyaluronate or hyaluronic acid, and the soluble corticosteroid is dexamethasone sodium phosphate and the insoluble corticosteroid is dexamethasone acetate, wherein the molecular weight of the at least one viscosity enhancing agent is between 1.0 MDa and 2.5 MDa, and wherein the concentration of the at least one viscosity enhancing agent is between 1.0% w/v and 1.5% w/v.

Syringe with insoluble and soluble corticosteroids selected as methylprednisolone salts or esters plus sodium hyaluronate or hyaluronic acid viscosity enhancer

A syringe comprising an aqueous pharmaceutical composition comprising an insoluble corticosteroid, a soluble corticosteroid, and at least one viscosity enhancing agent, wherein the at least one viscosity enhancing agent is sodium hyaluronate or hyaluronic acid, and the insoluble corticosteroid and soluble corticosteroid are selected from the group consisting of salts and esters of methylprednisolone, wherein the molecular weight of the at least one viscosity enhancing agent is between 1.0 MDa and 2.5 MDa, and wherein the concentration of the at least one viscosity enhancing agent is between 1.0% w/v and 1.5% w/v.

Across the two independent claims, the core claim coverage is directed to a syringe containing an aqueous pharmaceutical composition with both insoluble and soluble corticosteroids plus a sodium hyaluronate or hyaluronic acid viscosity enhancing agent, with the viscosity enhancer constrained to specified molecular-weight and concentration ranges. The independent claims further narrow corticosteroid identities to dexamethasone acetate and dexamethasone sodium phosphate in one case and to salts and esters of methylprednisolone in the other.

Stated Advantages

Improved injectability via reduced injection force thresholds.

Mitigation of stringing.

Improved administration characterized as a clean break.

Longer dosing intervals, about 4 to 24 weeks, are emphasized in the described therapeutic use.

Documented Applications

Local injection at injection sites including epidural space.

Local injection at injection sites including intra-articular injection.

Local injection at injection sites including intralesional injection.

Local injection at injection sites including intra-ocular injection.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.